Recently I had the privilege of meeting Dr. T Vollmer, a co-author of the article "B-Cell Depletion with Rituximab in RRMS" in the New England Journal of Medicine. Meeting Dr. Vollmer was the result of soliciting for participation in the Alemtuzumab (Campath) vs Rebif trial. Although we both shared the vision one should fight fire with fire, Alemtuzumab would be his last resort. Dr. Vollmer strong recommendation for a case like mine (RRMS), is Rituximab. One of the reasons for that is, unlike Alemtuzumab, Rituximab does not permanently alter the immune system, i.e. it is reversible over time. He expressed his expectation that the FDA is going to approve Rituximab soon after the article would be published. Lets hope so.